Dyne Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DYN research report →
Range $24 – $50
Price Chart
About the company
Dyne Therapeutics, Inc. is a U. S.
- CEO
- John G. Cox
- IPO
- 2020
- Employees
- 289
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on DYN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.85B
- P/E
- -7.80
- Fwd P/E
- 36.96
- PEG
- -0.54
- P/S
- 0.00
- P/B
- 6.12
- EV/EBITDA
- -8.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -64.30%
- ROIC
- -58.28%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,049,000+8.6%
- Op Income
- $-468,184,000
- Net Income
- $-446,214,000-40.6%
- EPS
- $-3.47-3.0%
- OCF Growth
- -37.9%
- FCF Growth
- -37.4%
- 52W High
- $27.30
- 52W Low
- $11.64
- 50D MA
- $23.22
- 200D MA
- $19.59
- Beta
- 1.08
- RSI (14)
- 57
- Avg Volume
- 2.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Dynegy reported a stronger second quarter on higher capacity revenues, the ENGIE acquisition contribution, and a one-time cash receipt, while reaffirming full-year guidance and doubling down on deleveraging and cost cuts.· August 4, 2017
- Adjusted EBITDA rose by $53 million to $240 million, helped by higher IPH capacity revenues, a $60 million contribution from ENGIE assets, and a $25 million one-time cash receipt.
- Management reaffirmed 2017 full-year adjusted EBITDA and adjusted free cash flow guidance despite energy margin pressure, saying hedges and cost control largely offset commodity weakness.
- Asset sales remain central to the deleveraging plan: finalized and announced transactions are expected to generate nearly $800 million of cash, with proceeds intended for debt paydown, especially the November 2019 maturity.
- Dynegy is launching a new PRIDE cost program focused on about $2 billion of operating expenses, plus working capital and capital spending, with most opportunities seen in the generation fleet.
- The company continues to push for market reform on ZEC subsidies and is increasing ERCOT hedges for 2018 as prices rise and coal-retirement expectations build into the market.
Dynegy said second-quarter 2017 adjusted EBITDA increased by $53 million to $240 million. The increase was driven by higher capacity revenues in the IPH segment, a $60 million contribution from assets acquired from ENGIE in February, and partially offset by lower energy margins; management also cited a one-time $25 million cash receipt that flowed through other income and EBITDA. On guidance, the company reaffirmed its 2017 full-year adjusted EBITDA and adjusted free cash flow ranges, with Bob Flexon saying the company was still in the same “zip code” as prior guidance. Management said the asset sale program to date, once finalized, should generate nearly $800 million in cash, which it plans to use to reduce debt, particularly the November 2019 maturity.
CEO Bob Flexon emphasized safety, saying recordable incident rates were top decile for a second straight quarter and down 40% since 2015. Strategically, he framed the quarter around deleveraging, portfolio optimization, and a new round of operating-cost improvement through PRIDE, saying the company is already a low-cost operator but still sees meaningful opportunity, mostly in the generation fleet. His tone was constructive and opportunistic: he repeatedly said Dynegy would pursue asset sales, retail growth, and market reforms only when they support leverage reduction and shareholder value.
CFO Clint Freeland explained that the $25 million was previously uncertain cash tied to an Ameren-era IPH item that was not budgeted in the original guidance and is now unrestricted cash on the balance sheet. He also confirmed the company’s guidance stance, saying the one-time item was not expected at the start of the year and that the company remains comfortable within its full-year range. On capital allocation, management said asset sale proceeds are intended to pay down debt, and that the company is actively managing hedges and costs to offset lower energy margins.
Analysts focused on the quality of earnings, the hedge profile, the new PRIDE program, and the pace/logic of asset sales. Management said the hedge changes mainly reflected higher expected generation from improved spark spreads, not hedge buybacks or earnings management, and that the cost program’s broad opportunity set is about $2.6 billion in total, with roughly $2 billion in operating expenses under review. On asset sales, Flexon said the market is softer and that Dynegy will only move forward with CCGT sales if the buyer universe and indicative bids support deleveraging; otherwise it will wait. Questions also centered on ZEC litigation and FERC/PJM reforms, with management saying it expects more action in 2018 and that FERC could direct ISOs to implement MOPR-style fixes or act on pending complaints.
The call’s bull case is that Dynegy is still producing solid EBITDA despite lower energy margins, while getting support from acquisitions, capacity revenues, and a one-time cash inflow. Management sounded confident that asset sales and PRIDE can drive meaningful additional deleveraging, and it highlighted a large opportunity set in fleet operations, procurement, and working capital. The company also sees supportive momentum in retail growth, ERCOT hedging, and market reform efforts.
The main risks discussed were softer energy margins, an uneven asset-sale market, and ongoing pressure from state subsidy programs in Illinois and New York. Management also acknowledged that some plants may face shutdown or sale if they cannot remain free-cash-flow positive, especially if future environmental capex is not justified by pricing. The call also showed that the company is still dependent on external market reforms and FERC/ISO action to fully neutralize ZEC-related distortions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.6%
- Shares Outstanding
- 186.75M
- Float Shares
- 152.33M
of shares held by institutions
236 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | ▲ 126.49K |
| Janus Henderson Group PLC | 13.65M | ▼ 240.35K |
| Blackrock, Inc. | 12.40M | ▲ 704.46K |
| Vanguard Group Inc | 11.22M | ▲ 1.46M |
| Fmr LLC | 11.21M | ▲ 2.30M |
| State Street Corp | 7.46M | ▲ 804.52K |
| Orbis Allan Gray Ltd | 7.01M | ▲ 244.31K |
| Atlas Venture Life Science Advisors, LLC | 6.80M | ▼ 2.33M |
| Vanguard Capital Management LLC | 6.31M | ▼ 94.10K |
| Tcg Crossover Management, LLC | 4.62M | 0 |
| Price T Rowe Associates Inc | 3.94M | ▲ 1.61M |
| Fcpm Iii Services B.V. | 3.85M | ▼ 796.13K |
Held by 235 ETFs
Biggest fund positions in DYN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 26 | Rhodes Jason P | sell | 268,354 |
| Aug 14, 26 | Rhodes Jason P | sell | 1,359,674 |
| Aug 13, 26 | Rhodes Jason P | sell | 94,415 |
| Aug 13, 26 | Rhodes Jason P | sell | 63,643 |
| Aug 14, 26 | Rhodes Jason P | sell | 478,377 |
| Aug 14, 26 | Rhodes Jason P | sell | 322,465 |
| Aug 13, 26 | Friedl-Naderer Johanna | sell | 226 |
| Aug 13, 26 | Kerr Douglas | sell | 1,556 |
| Aug 13, 26 | Cox John | sell | 4,986 |
| Aug 13, 26 | Lucera Erick | sell | 1,797 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DYN coverage
Recent articles, reports, and earnings notes.
No research on DYN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DYN report →Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 20
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Jul 29
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
globenewswire.com · Jul 28
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN
defenseworld.net · Jul 27
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 24
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
globenewswire.com · Jul 23
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
globenewswire.com · Jul 21
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
globenewswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.